Tiger Brokers

【大行评级｜花旗：上调巨子生物目标价至78.1港元 维持“买入”评级】花旗发表研报指，巨子生物2024财年净利润增长42%，符合预期；收入增长57%，超出预期，抵销了较高的销售与分销费用。该行提及，巨子生物管理层目标于2025财年实现收入增长25%至28%，净利润目标增长21%至24%。此外，管理层对今年首季表现感到满意，特别是妇女节促销，令管理层对实现全年目标有信心。该行将巨子生物目标价由68.2港元上调至78.1港元，维持“买入”评级。

金融界
28 Mar
花旗发表研报指，巨子生物2024财年净利润增长42%，符合预期；收入增长57%，超出预期，抵销了较高的销售与分销费用。该行提及，巨子生物管理层目标于2025财年实现收入增长25%至28%，净利润目标增长21%至24%。此外，管理层对今年首季表现感到满意，特别是妇女节促销，令管理层对实现全年目标有信心。该行将巨子生物目标价由68.2港元上调至78.1港元，维持“买入”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10